Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Leuprolide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GNRHR known ✓ | P30968 | 2/20 | 0.74 |
| ▸ | ABCC2 | Q92887 | 1/20 | 0.72 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.68 |
| ▸ | C5AR1 | P21730 | 2/20 | 0.59 |
| ▸ | APLNR | P35414 | 4/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28690690 | 1.00 | GNRHR (0.74) | GNRHRABCC2PTGS1C5AR1APLNR | |
| SCHEMBL29588982 | 1.00 | GNRHR (0.74) | GNRHRABCC2PTGS1C5AR1APLNR | |
| Deslorelin SCHEMBL59413 | 1.00 | GNRHR (0.74) | GNRHRABCC2PTGS1C5AR1APLNR | |
| SCHEMBL29750348 | 1.00 | GNRHR (0.74) | GNRHRABCC2PTGS1C5AR1APLNR | |
| Deslorelin SCHEMBL25353366 | 1.00 | GNRHR (0.74) | GNRHRABCC2PTGS1C5AR1APLNR | |
| Leuprolide SCHEMBL25418953 | 1.00 | GNRHR (0.74) | GNRHRABCC2PTGS1C5AR1APLNR | |
| Leuprolide SCHEMBL14190828 | 1.00 | GNRHR (0.74) | GNRHRABCC2PTGS1C5AR1APLNR | |
| Deslorelin SCHEMBL29350981 | 1.00 | GNRHR (0.74) | GNRHRABCC2PTGS1C5AR1APLNR | |
| SCHEMBL29833896 | 1.00 | GNRHR (0.74) | GNRHRABCC2PTGS1C5AR1APLNR | |
| Leuprolide SCHEMBL28615809 | 0.99 | GNRHR (0.73) | GNRHRABCC2PTGS1C5AR1APLNR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 856 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3841097-B1 | 2,6-BIS(((1H-BENZO[D]IMIDAZOL-2-YL)THIO)METHYL)PYRIDINE AND N2,N6-DIBENZYLPYRIDINE-2,6-DICARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS PHOSPHOINOSITIDE 3-KINASE (PI3K) INHIBITORS FOR TREATING CANCER | BIOMEDICAL RES FOUNDATION OF THE ACADEMY OF ATHENS BRFAA (GR) | 2026-05-20 | — | — | EP | claimed |
| US-20260116861-A1 | ISOXAZOLE HYDROXAMIC ACIDS AS HISTONE DEACETYLASE 6 INHIBITORS | THE GEORGE WASHINGTON UNIVERSITY, A CONGRESSIONALLY CHARTERED NOT-FOR-PROFIT CORPORATION (US) | 2026-04-30 | — | — | US | claimed |
| US-20260108619-A1 | CONJUGATION LINKERS, CELL BINDING MOLECULE-DRUG CONJUGATES CONTAINING THE LINKERS, METHODS OF MAKING AND USES SUCH CONJUGATES WITH THE LINKERS | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2026-04-23 | — | — | US | claimed |
| EP-3515892-B1 | COMPOUNDS AND METHODS FOR IDO AND TDO MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC (US) | 2026-04-15 | — | — | EP | claimed |
| EP-4720216-A1 | USES OF NOVEL LUMINESCENT SURFACTANT COMPOUNDS | North-West University (ZA) | 2026-04-08 | — | — | EP | claimed |
| EP-4720032-A2 | NOVEL SURFACTANT COMPOUNDS | North-West University (ZA) | 2026-04-08 | — | — | EP | claimed |
| EP-4420657-B1 | MICROPARTICLES CONTAINING LEUPROLIDE, AND PREPARATION METHOD THEREOF | INVENTAGE LAB INC (KR) | 2026-02-18 | — | — | EP | claimed |
| EP-4209246-B1 | METHOD OF MANUFACTURING OF A PARTICLE-ATTACHED MICRONEEDLE | QUADMEDICINE INC (KR) | 2026-02-18 | — | — | EP | claimed |
| EP-4680284-A2 | BIODEGRADABLE DENDRITIC PARTICLES FOR SUSTAINED DRUG RELEASE | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) | 2026-01-21 | — | — | EP | claimed |
| US-12527764-B2 | Methods and compositions for treating androgen receptor deficient, androgen receptor low, and castration-resistant prostate cancers | FRED HUTCHINSON CANCER CENTER (US) | 2026-01-20 | — | — | US | claimed |
| EP-3551761-B1 | HER2 AS A PREDICTOR OF RESPONSE TO DUAL HER2 BLOCKADE IN THE ABSENCE OF CYTOTOXIC THERAPY | FUNDACIO PRIVADA INST DINVESTIGACIO ONCOLÒGICA DE VALL HEBRON (ES) | 2022-03-16 | — | — | EP | claimed |
| EP-3586828-B1 | METHOD FOR PREPARING BIODEGRADABLE MICROSPHERES HAVING IMPROVED STABILITY AND STORAGE STABILITY | G2GBIO INC (KR) | 2022-03-02 | — | — | EP | claimed |
| EP-3359129-B1 | ZINC COMPOSITIONS FOR COATED MICRONEEDLE ARRAYS | KINDEVA DRUG DELIVERY LP (US) | 2022-02-23 | — | — | EP | claimed |
| EP-3693375-B1 | COMPOSITIONS AND METHODS FOR INHIBITING ARGINASE ACTIVITY | CALITHERA BIOSCIENCES INC (US) | 2022-02-16 | — | — | EP | claimed |
| CN-114040779-A | Conjugates of cell binding molecules containing branched linkers and cytotoxic agents | 杭州多禧生物科技有限公司 | 2022-02-11 | — | — | CN | claimed |
| US-20090005535-A1 | Solution-Phase Synthesis of Leuprolide and Its Intermediates | NANOKEM S.A. (UY) | 2009-01-01 | — | — | US | claimed |
| EP-1790656-A1 | Solution-phase synthesis of leuprolide | NANOKEM S.A. (UY) | 2007-05-30 | — | — | EP | claimed |
| US-4800085-A | Slow-release composite and process for producing the same | JAPAN ATOMIC ENERGY RESEARCH INSTITUTE (JP) | 1989-01-24 | — | — | US | claimed |
| US-4652443-A | Slow-release composite and process for producing the same | JAPAN ATOMIC ENERGY RESEARCH INSTITUTE (JP) | 1987-03-24 | — | — | US | claimed |
| EP-0130409-A2 | Slow-release composite and process for producing the same | Takeda Chemical Industries, Ltd. (JP) | 1985-01-09 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12527764-B2 | Methods and compositions for treating androgen receptor deficient, androgen receptor low, and castration-resistant prostate cancers | EIF4E, EIF4EBP1, EIF4A2 | GNRHR 426/4885ABCC2 4309/4885PTGS1 1397/4885 |
| US-20260116861-A1 | ISOXAZOLE HYDROXAMIC ACIDS AS HISTONE DEACETYLASE 6 INHIBITORS | HDAC3, HDAC1, HDAC4 | GNRHR 627/4885ABCC2 699/4885PTGS1 4049/4885 |
| US-20260108619-A1 | CONJUGATION LINKERS, CELL BINDING MOLECULE-DRUG CONJUGATES CONTAINING THE LINKERS, METHODS OF MAKING AND USES SUCH CONJUGATES WITH THE LINKERS | DCLRE1A, CCR3, CCR8 | GNRHR 289/4885ABCC2 440/4885PTGS1 3450/4885 |
| US-20090005535-A1 | Solution-Phase Synthesis of Leuprolide and Its Intermediates | LPXN, GNRHR, LHCGR | GNRHR 2/4885ABCC2 4885/4885PTGS1 1267/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.